Product Name: tert-Butyl [(1R,2S,5S)-2-amino-5-[(dimethylamino)carbonyl]cyclohexyl]carbamate (Edoxaban Intermediate)
CAS No.: 365998-36-3
🔬 Product Overview
A high-purity pharmaceutical intermediate critical for synthesizing Edoxaban (CAS 480449-70-5), a leading direct oral anticoagulant (DOAC) used to prevent stroke and systemic embolism in patients with atrial fibrillation. With ≥98% purity (HPLC-certified), it ensures precision in API manufacturing and R&D for next-generation thrombin inhibitors. Available in bulk quantities (1kg–25kg) with industrial-grade packaging options.
📊 Key Advantages
✅ High Purity: ≥98% (up to 99% by HPLC/GC), minimizing impurities in API synthesis.
📦 Scalable Supply: Customizable packaging (1kg, 5kg, 25kg) for lab and industrial use.
🔍 Batch Traceability: COA provided for compliance with pharmaceutical standards.
💊 Applications
Anticoagulant Production: Core intermediate for Edoxaban API synthesis.
R&D of Thrombin Inhibitors: Supports development of novel cardiovascular drugs.
Global Export: Widely used in pharmaceutical and chemical reagent markets.
📜 Quality Certification
Testing Standards: HPLC, GC, NMR, and mass spectrometry.
Compliance: Meets ISO 9001 and ICH Q7 guidelines for intermediates.
🌍 Market Trends
Demand for Edoxaban intermediates is rising due to patent expirations (2024–2026) and increasing global prevalence of cardiovascular diseases. The DOAC market is projected to grow at 8.4% CAGR (2025–2030), driven by aging populations and demand for cost-effective generics. Asia-Pacific dominates API production, with suppliers offering GMP-ready batches gaining market share.
China
